SEGMENTS (Details)	3 Months Ended						9 Months Ended
	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2022 USD ($) Facility	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Segment Reporting Information [Abstract]
Number of plasma collection facilities | Facility							10
Number of FDA-licensed plasma collection facilities | Facility							7
Number of additional plasma collections centers in operation and collection of plasma | Facility							2
Number of remaining plasma collection facilities under construction | Facility							1
Revenues	$ 41,090,137			$ 20,680,550			$ 104,098,237	$ 54,559,758
Cost of product revenue	31,433,496			20,295,213			83,010,156	56,897,959
Income (loss) from operations	(9,316,733)			(14,437,076)			(33,306,538)	(45,182,557)
Interest and other expense, net	(5,582,771)			(3,275,878)			(13,695,788)	(9,815,641)
Loss on extinguishment of debt	0			0			(6,669,941)	0
Net income (loss)	(14,899,504)	$ (13,764,906)	$ (25,007,857)	(17,712,954)	$ (18,905,303)	$ (18,379,941)	(53,672,267)	(54,998,198)
Capital expenditures							10,162,650	9,835,404
Total assets	300,557,570			238,640,406			300,557,570	238,640,406	$ 276,252,724
Depreciation and amortization expense	1,861,992			1,422,164			5,176,492	3,977,786
United States [Member]
Segment Reporting Information [Abstract]
Revenues	37,854,167			18,265,945			96,445,162	47,368,793
International [Member]
Segment Reporting Information [Abstract]
Revenues	3,235,970			2,414,605			7,653,075	7,190,965
Corporate [Member]
Segment Reporting Information [Abstract]
Revenues	35,708			35,708			107,125	107,125
Cost of product revenue	0			0			0	0
Income (loss) from operations	(4,977,774)			(3,817,061)			(16,363,147)	(11,954,388)
Interest and other expense, net	(5,579,594)			(3,297,103)			(13,624,483)	(9,735,808)
Loss on extinguishment of debt							(6,669,941)
Net income (loss)	(10,557,368)			(7,114,164)			(36,657,571)	(21,690,196)
Capital expenditures							0	0
Total assets	18,448,139			27,347,259			18,448,139	27,347,259
Depreciation and amortization expense	0			1,174			918	4,571
Operating Segments [Member] | ADMA BioManufacturing [Member]
Segment Reporting Information [Abstract]
Revenues	37,280,798			19,063,077			95,129,542	48,832,000
Cost of product revenue	27,883,046			18,695,783			74,383,948	51,527,832
Income (loss) from operations	297,310			(7,456,129)			(4,423,228)	(25,299,223)
Interest and other expense, net	(3,023)			22,822			(70,084)	(77,484)
Loss on extinguishment of debt							0
Net income (loss)	294,287			(7,433,307)			(4,493,312)	(25,376,707)
Capital expenditures							4,292,246	3,805,472
Total assets	242,983,498			189,019,883			242,983,498	189,019,883
Depreciation and amortization expense	1,214,529			1,064,757			3,486,212	3,130,064
Operating Segments [Member] | Plasma Collection Centers [Member]
Segment Reporting Information [Abstract]
Revenues	3,773,631			1,581,765			8,861,570	5,620,633
Cost of product revenue	3,550,450			1,599,430			8,626,208	5,370,127
Income (loss) from operations	(4,636,269)			(3,163,886)			(12,520,163)	(7,928,946)
Interest and other expense, net	(154)			(1,597)			(1,221)	(2,349)
Loss on extinguishment of debt							0
Net income (loss)	(4,636,423)			(3,165,483)			(12,521,384)	(7,931,295)
Capital expenditures							5,870,404	6,029,932
Total assets	39,125,933			22,273,264			39,125,933	22,273,264
Depreciation and amortization expense	$ 647,463			$ 356,233			$ 1,689,362	$ 843,151